Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN XR versus UNASYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN XR versus UNASYN.
AUGMENTIN XR vs UNASYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a beta-lactam antibacterial that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamase enzymes, protecting amoxicillin from degradation.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); sulbactam is a beta-lactamase inhibitor that prevents degradation of ampicillin by beta-lactamases.
Adults and adolescents ≥16 years: 2 tablets (amoxicillin 1000 mg/clavulanate 62.5 mg per tablet) orally every 12 hours for 10 days.
3 g (ampicillin 2 g + sulbactam 1 g) IV every 6 hours; total daily dose of sulbactam not to exceed 4 g.
None Documented
None Documented
Amoxicillin: ~1.0-1.3 hours; clavulanate: ~0.9-1.2 hours; prolonged in renal impairment (creatinine clearance <30 mL/min: amoxicillin half-life up to 7-14 hours).
Ampicillin: ~1 hour (normal renal function); sulbactam: ~1-1.4 hours (normal renal function); prolonged in renal impairment (ampicillin up to 20 hours, sulbactam up to 10-15 hours in anuria).
Amoxicillin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; clavulanate: ~25-40% excreted unchanged in urine; both undergo minor biliary/fecal elimination (<10%).
Renal: ampicillin (~75-90% unchanged) and sulbactam (~75-85% unchanged); biliary/fecal: minimal (<5% for each component).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic